1. Home
  2. PUMP vs DRUG Comparison

PUMP vs DRUG Comparison

Compare PUMP & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProPetro Holding Corp.

PUMP

ProPetro Holding Corp.

HOLD

Current Price

$10.24

Market Cap

1.0B

Sector

Energy

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$87.60

Market Cap

856.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PUMP
DRUG
Founded
2007
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Oilfield Services/Equipment
Pharmaceuticals and Biotechnology
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
856.4M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
PUMP
DRUG
Price
$10.24
$87.60
Analyst Decision
Buy
Strong Buy
Analyst Count
8
8
Target Price
$12.14
$104.00
AVG Volume (30 Days)
1.7M
278.0K
Earning Date
02-18-2026
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,300,037,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.51
$23.18
52 Week High
$11.66
$123.75

Technical Indicators

Market Signals
Indicator
PUMP
DRUG
Relative Strength Index (RSI) 58.64 54.60
Support Level $9.13 $85.65
Resistance Level $10.97 $92.00
Average True Range (ATR) 0.50 8.78
MACD 0.10 -0.36
Stochastic Oscillator 60.33 29.67

Price Performance

Historical Comparison
PUMP
DRUG

About PUMP ProPetro Holding Corp.

ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: